Jaswant S. Gidda
Chief Executive Officer at Anagin, Inc.
Profile
Jaswant S.
Gidda is currently the President, Chief Executive Officer & Director at Anagin, Inc. Previously, he worked as a Senior Research Advisor at Eli Lilly & Co., Vice President-Research & Development at Marcadia Biotech, Inc., and Vice President-Research & Development at Naurex, Inc. Gidda received his undergraduate degree from Government College of Technology and his graduate and doctorate degrees from Panjab University Chandigarh.
Jaswant S. Gidda active positions
| Companies | Position | Start |
|---|---|---|
Anagin, Inc.
 Anagin, Inc. Pharmaceuticals: MajorHealth Technology Anagin, Inc. develops targeted therapies for pathologies associated with disrupted synaptic plasticity in the central nervous system leading to psychiatric diseases. It targeted diseases such as post traumatic stress disorder (PTSD), traumatic brain injury (TBI), depression, neuropathic pain, Alzheimer’s disease and Parkinson’s disease. The company was founded by Anatha Shekhar and Yvonne Lai in 2013 and is headquartered in Indianapolis, IN. | Chief Executive Officer | - |
Former positions of Jaswant S. Gidda
| Companies | Position | End |
|---|---|---|
Naurex, Inc.
 Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | Chief Tech/Sci/R&D Officer | - |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Marcadia Biotech, Inc.
 Marcadia Biotech, Inc. Pharmaceuticals: MajorHealth Technology Marcadia Biotech, Inc. develops therapeutic products for diabetes and obesity. It is a biopharmaceutical company focuses on developing a broad portfolio of drug candidates for treatment of diabetes and obesity. The company was founded in 2005 and is headquartered in Carmel, IN. | Chief Tech/Sci/R&D Officer | - |
Training of Jaswant S. Gidda
| Government College of Technology | Undergraduate Degree |
| Panjab University Chandigarh | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| Private companies | 3 |
|---|---|
Marcadia Biotech, Inc.
Marcadia Biotech, Inc. Pharmaceuticals: MajorHealth Technology Marcadia Biotech, Inc. develops therapeutic products for diabetes and obesity. It is a biopharmaceutical company focuses on developing a broad portfolio of drug candidates for treatment of diabetes and obesity. The company was founded in 2005 and is headquartered in Carmel, IN. | Health Technology |
Naurex, Inc.
Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | Health Technology |
Anagin, Inc.
Anagin, Inc. Pharmaceuticals: MajorHealth Technology Anagin, Inc. develops targeted therapies for pathologies associated with disrupted synaptic plasticity in the central nervous system leading to psychiatric diseases. It targeted diseases such as post traumatic stress disorder (PTSD), traumatic brain injury (TBI), depression, neuropathic pain, Alzheimer’s disease and Parkinson’s disease. The company was founded by Anatha Shekhar and Yvonne Lai in 2013 and is headquartered in Indianapolis, IN. | Health Technology |
- Stock Market
- Insiders
- Jaswant S. Gidda
